mProX™ Human P2RY2 Stable Cell Line

Product Information

Target Protein

P2RY2

Target Family

P2Y Family

Target Protein Species

Human

Host Cell Type

MK72; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Inflammation Research; Ocular Research

Related Diseases

Dry Eye Syndrome; Accommodative Spasm

Gene ID

5029

UniProt ID

P41231

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ATP and UTP, which are P2RY2's natural agonists, stimulate P2RY2's activity. P2RY2 was activated, and like other typical G protein receptors, the intracellular C-terminal of P2RY2 interacted with the G-protein, causing the intracellular C-terminal of P2RY2 to be phosphorylated and leading to a number of physiological reactions. Initiating early inflammatory responses and mediating later regenerative responses necessary for wound healing, cell migration, and liver regeneration are essential functions of P2RY2. Since P2RY2 is widely distributed throughout the body's tissues and has pathophysiological functions in a variety of functional areas, including immunological disorders, cancer progression, and lung diseases. It is a potential therapeutic target for the condition known as dry eye. The first P2RY2 agonist is a medication called diquafosol tetrasodium, which is used to treat dry eye condition. Many agonists that target P2RY2 are currently being developed to treat various disorders. The customized P2RY2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat James

The prices are unbeatable, and the selection is great. I will customize cell line again. Aug 17 2023

chat Verified Customer

chat Mia

The Human P2RY2 Stable Cell Line is so great! Dec 18 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 CRISPR-Cas9-mediated P2ry2 knockout.

ERK1/2 phosphorylated at Thr202/Tyr204 or total ERK1/2 were used as loading controls in an immunoblot analysis after MK72 cells were treated with or without 100 μM UTP for the respective durations.

Ref: Forti, Kevin Muñoz, et al. "Tumoral P2Y2 receptor modulates tumor growth and host anti-tumor immune responses in a syngeneic murine model of oral cancer." Purinergic Signalling (2023): 1-12.

Pubmed: 37572177

DOI: 10.1007/s11302-023-09960-z

Research Highlights

The cause of the chronic autoimmune disease Systemic Lupus Erythematosus (SLE) is unknown, however genetically predisposed individuals are likely to be affected by environmental factors.
Lessard, Christopher J., et al. "Identification of a systemic lupus erythematosus risk locus spanning ATG16L2, FCHSD2, and P2RY2 in Koreans." Arthritis & rheumatology 68.5 (2016): 1197-1209.
Pubmed: 26663301 DOI: 10.1002/art.39548

The nucleotides released by tumor cells and acting through the P2RY2 receptor are strongly suggested to be potential regulators of invasiveness because treatment with apyrase inhibits the migration of control cells and induces a significant enrichment of E-cadherin in the cell-cell contacts, favoring an epithelial phenotype.
Martínez-Ramírez, A. S., et al. "The P2RY2 receptor induces carcinoma cell migration and EMT through cross-talk with epidermal growth factor receptor." Journal of cellular biochemistry 117.4 (2016): 1016-1026.
Pubmed: 26443721 DOI: 10.1002/jcb.25390